In patients with malignant melanoma, PTEN deletion is associated with reduced tumor site T cell infiltration, a lower chance of T cell growth following tumor excision, and inferior PD-1 inhibitor therapy (20). This evidence concerns the gene PDCD1 and neoplasm.